Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
54 hedge funds and large institutions have $30.9M invested in Kezar Life Sciences in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 9 reducing their positions, and 12 closing their positions.
122% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 9
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
0% more funds holding
Funds holding: 54 → 54 (0)
0.31% less ownership
Funds ownership: 5.24% → 4.92% (-0.31%)
60% less capital invested
Capital invested by funds: $77.2M → $30.9M (-$46.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$434K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$431K |
| 3 |
Renaissance Technologies
New York
|
+$390K |
| 4 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$307K |
| 5 |
Two Sigma Advisers
New York
|
+$306K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.5M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
-$1.16M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$534K |
| 4 |
BCP
Berylson Capital Partners
Boston,
Massachusetts
|
-$424K |
| 5 |
Morgan Stanley
New York
|
-$331K |
KZR Hedge Fund Activity: Q3 2019 in Review
54 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q3 2019, worth a combined $30.9M — down 60% from $77.2M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new KZR positions and 12 closed out — a net gain of 1 holder — while 20 added to existing stakes and 9 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $434K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $4.5M sold.
- 54 institutional investors held Kezar Life Sciences (KZR) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $30.9M of Kezar Life Sciences stock for Q3 2019, down 60% quarter-over-quarter.
- 13 funds opened new Kezar Life Sciences positions in Q3 2019 and 12 closed out, a net change of +1 holder.
- The largest Kezar Life Sciences buyer in Q3 2019 was Two Sigma Investments, an estimated $434K added.
- The largest Kezar Life Sciences seller in Q3 2019 was EcoR1 Capital, an estimated $4.5M sold.
Based on aggregated 13F filings for Q3 2019.